Daily Archives: November 9, 2020

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC/TDF for the Prevention of HIV

Both cabotegravir and oral FTC/TDF have high efficacy for PrEP among women in sub-Saharan Africa Durham, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent […]

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC/TDF for the Prevention of HIV

Both cabotegravir and oral FTC/TDF have high efficacy for PrEP among women in sub-Saharan Africa Durham, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein […]

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein

Constellation Brands and E. & J. Gallo Sign Agreement With Federal Trade Commission Staff Relating to Consent Order on Pending Transaction; Constellation Provides Business Update for Fiscal 2021

VICTOR, N.Y., Nov. 09, 2020 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it and E. & J. Gallo Winery have signed an Agreement Containing Consent Order with the Bureau of Competition of the U.S. Federal Trade Commission (FTC) regarding Gallo’s pending acquisition of a […]